Foresight Biosciences commercializes technology for glycobiology research with an emphasis on creating tools for engineering glycoconjugates that alter the biodistribution of administered therapeutics.


Most FDA approved protein therapeutics are glycosylated. Natural protein glycoconjugates have very specific structures that affect their function and distribution. Therapeutic proteins derived from nonhuman cells often exhibit improper glycosylation that require modification prior to administration.

The company’s technology facilitates protein posttranslational modification, glycoconjugation, and glycan analysis.

Product & Service

The company offers benchtop assays for glycoprotein terminal fingerprint analysis, recombinant enzymes, and convenient kits for identifying, repairing and modifying protein glycosylation.

Ronny Hughes, PhD

Ernest Curto, PhD
Senior Scientist

All resident associate companies on the HudsonAlpha campus are independently owned and operated.